Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AZD9291”

293 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 293 results

Large-scale testing (Phase 3)Looking for participantsNCT05382728
What this trial is testing

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Who this might be right for
NSCLCEGFR Activating Mutation
TYK Medicines, Inc 680
Early research (Phase 1)UnknownNCT04448379
What this trial is testing

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 48
Testing effectiveness (Phase 2)Study completedNCT03434418
What this trial is testing

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Who this might be right for
Non Small Cell Lung Cancer
Duke University 17
Not applicableActive Not RecruitingNCT07491211
What this trial is testing

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastases From Non-small Cell Lung Cancer (NSCLC)Osimertinib+1 more
Fudan University 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT05773092
What this trial is testing

Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Who this might be right for
NSCLC
National Cancer Centre, Singapore 30
Not applicableLooking for participantsNCT06068049
What this trial is testing

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 500
Not applicableLooking for participantsNCT05033691
What this trial is testing

Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

Who this might be right for
NSCLCEGFR Gene MutationEGF-R Positive Non-Small Cell Lung Cancer+2 more
Hadassah Medical Organization 162
Testing effectiveness (Phase 2)UnknownNCT03804580
What this trial is testing

First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Vestre Viken Hospital Trust 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122717
What this trial is testing

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute 48
Large-scale testing (Phase 3)UnknownNCT02972333
What this trial is testing

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Who this might be right for
EGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more
Shandong Cancer Hospital and Institute 150
Not applicableTemporarily pausedNCT05421936
What this trial is testing

Osimertinib for NSCLC With Uncommon EGFR Mutations

Who this might be right for
Carcinoma, Non-Small-Cell LungGenes, erbB-1
Sheba Medical Center 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03433469
What this trial is testing

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Who this might be right for
Stage I Non-Small Cell Lung CancerStage IA Non-Small Cell Lung CancerStage IB Non-Small Cell Lung Cancer+4 more
University of California, San Francisco 27
Large-scale testing (Phase 3)UnknownNCT05104281
What this trial is testing

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Qingdao Central Hospital 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167
What this trial is testing

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 19
Large-scale testing (Phase 3)Active Not RecruitingNCT05020769
What this trial is testing

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 14
Not applicableActive Not RecruitingNCT07303218
What this trial is testing

The HER Project: HRD in EGFR-mutated NSCLC

Who this might be right for
EGFRNon Small Cell Lung CancerHomologous Recombination Deficiency+1 more
IRCCS San Raffaele 100
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Not applicableWithdrawnNCT02368990
What this trial is testing

T790M Mutation Positive 2nd Line STandard of cAre Registry

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca
Large-scale testing (Phase 3)UnknownNCT04870190
What this trial is testing

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Who this might be right for
NSCLC
Shanghai Chest Hospital 232
Testing effectiveness (Phase 2)Study completedNCT04770688
What this trial is testing

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR MutationLocally Advanced Solid TumorMetastatic Cancer+1 more
Shanghai Chest Hospital 25
Load More Results